Immunovant Shares Drop 10% After Batoclimab Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy IMVT?
Source: seekingalpha
- Trial Failure Announcement: Immunovant reported that its late-stage program for batoclimab failed to meet the primary endpoint in two Phase 3 trials for thyroid eye disease, resulting in a ~10% drop in premarket shares.
- Stable Safety Data: Despite the trial failures, both studies indicated safety data consistent with previous findings, with no new safety signals, providing a foundation for future research efforts.
- Future Development Plans: The company stated it will share updates on batoclimab's development program after reviewing plans with its South Korean partner, HanAll Biopharma, indicating ongoing commitment to the project.
- Advancement of New Therapy: Immunovant intends to expedite the clinical advancement of IMVT-1402, with topline data from potentially registrational studies for Graves' disease expected next year, showcasing a new strategic direction for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMVT
Wall Street analysts forecast IMVT stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 25.100
Low
22.00
Averages
37.00
High
54.00
Current: 25.100
Low
22.00
Averages
37.00
High
54.00
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunovant Reports Disappointing Trial Results, Shares Drop
- Clinical Trial Results: Immunovant's two late-stage trials failed to meet the primary endpoint, although patients showed significant improvement in eye bulging during the initial 12-week high-dose treatment, indicating the potential importance of IgG antibody suppression.
- Stock Reaction: Following the disappointing topline results, Immunovant (IMVT) shares fell 12% in pre-market trading, and if this level holds after the opening bell, it would mark the lowest point in nearly four months, reflecting market pessimism about its future prospects.
- Shift in Treatment Focus: Immunovant plans to shift its focus to the development of IMVT-1402, targeting multiple autoimmune diseases with Graves' disease as a priority, and early Phase 2 data suggest this therapy may help modify the disease, with topline results from late-stage studies expected in 2027.
- Intensifying Market Competition: In the same week that Immunovant reported its results, Viridian Therapeutics (VRDN) also announced its Phase 3 results for treating thyroid eye disease, which met its primary goal but showed limited improvements in inflammation, highlighting the competitive intensity in this therapeutic area.
See More
Immunovant's Phase 3 Trials Fail to Meet Primary Endpoints
- Trial Results: Immunovant's Phase 3 trials of Batoclimab for Thyroid Eye Disease failed to meet primary endpoints, resulting in an 8.12% pre-market drop to $23.06, indicating investor concerns about the company's future prospects.
- Treatment Analysis: The trials evaluated a regimen of 680mg of Batoclimab administered subcutaneously once weekly for 12 weeks, followed by 340mg weekly, but failed to achieve a 2mm or greater improvement in proptosis responder rate at Week 24, reflecting insufficient efficacy in this indication.
- Patient Response Insights: Despite not meeting primary endpoints, the studies indicated that patients showed greater proptosis improvement during the initial high-dose phase, suggesting that deeper IgG suppression may positively influence treatment outcomes, which could impact future drug development strategies.
- Future Development Plans: Immunovant intends to review future development plans for Batoclimab with partner HanAll Biopharma and remains focused on advancing IMVT-1402 across multiple autoimmune diseases, with topline data for Graves' disease expected in 2027, demonstrating the company's long-term commitment to this area.
See More
Immunovant Shares Drop 10% After Batoclimab Trial Failure
- Trial Failure Announcement: Immunovant reported that its late-stage program for batoclimab failed to meet the primary endpoint in two Phase 3 trials for thyroid eye disease, resulting in a ~10% drop in premarket shares.
- Stable Safety Data: Despite the trial failures, both studies indicated safety data consistent with previous findings, with no new safety signals, providing a foundation for future research efforts.
- Future Development Plans: The company stated it will share updates on batoclimab's development program after reviewing plans with its South Korean partner, HanAll Biopharma, indicating ongoing commitment to the project.
- Advancement of New Therapy: Immunovant intends to expedite the clinical advancement of IMVT-1402, with topline data from potentially registrational studies for Graves' disease expected next year, showcasing a new strategic direction for the company.
See More
Logos Increases Immunovant Stake to $35 Million
- Significant Stake Increase: Logos Global Management LP purchased an additional 1.1 million shares of Immunovant in Q4 2025, with an estimated transaction value of $24.5 million, reflecting strong confidence in the company's potential.
- Value Growth: By the end of the quarter, Logos' total stake in Immunovant rose to approximately $35 million, indicating a substantial increase driven by both new shares and price appreciation, highlighting its importance in the fund's portfolio.
- Portfolio Allocation Shift: The stake in Immunovant increased from 0.4% to about 2%, which, while not placing it in the top five holdings, signifies a meaningful commitment within a concentrated portfolio, showcasing Logos' focus on the biotech sector.
- Clinical Progress Monitoring: Immunovant is advancing batoclimab across multiple autoimmune indications, with key Phase 3 study results expected in the first half of 2026, which will significantly impact its regulatory trajectory.
See More
Logos Global Management Increases Immunovant Stake to 1.375 Million Shares
- Significant Stake Increase: Logos Global Management LP disclosed an increase of 1,100,000 shares in Immunovant during Q4 2025, with an estimated transaction value of $24.5 million, indicating strong confidence in the company's clinical trial progress.
- Value Growth of Holdings: This acquisition brings Logos' total holdings in Immunovant to 1,375,000 shares, valued at approximately $34.95 million, representing 2.11% of its assets under management, highlighting the fund's focus on the biotech sector.
- Strong Market Performance: As of March 13, 2026, Immunovant shares were priced at $24.72, reflecting a 29.3% increase over the past year, outperforming the S&P 500 by 10.58%, showcasing its competitive edge and investment appeal.
- Clinical Trial Developments: Immunovant's lead candidate, batoclimab, has completed Phase III trials for myasthenia gravis and is currently in Phase III trials for thyroid eye disease, with results expected in the first half of 2026, which will significantly impact its regulatory path.
See More
S&P 500 Futures Rise in Pre-Market Session; Adobe and Ulta Beauty Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Klarna Group Performance: Klarna Group PLC (KLAR) saw a 6.4% increase in pre-market trading.
Legence Corp Performance: Legence Corp. (LGN) experienced a 4.4% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate a positive sentiment ahead of the market opening.
See More
Immunovant Reports Disappointing Trial Results, Shares Drop
- Clinical Trial Results: Immunovant's two late-stage trials failed to meet the primary endpoint, although patients showed significant improvement in eye bulging during the initial 12-week high-dose treatment, indicating the potential importance of IgG antibody suppression.
- Stock Reaction: Following the disappointing topline results, Immunovant (IMVT) shares fell 12% in pre-market trading, and if this level holds after the opening bell, it would mark the lowest point in nearly four months, reflecting market pessimism about its future prospects.
- Shift in Treatment Focus: Immunovant plans to shift its focus to the development of IMVT-1402, targeting multiple autoimmune diseases with Graves' disease as a priority, and early Phase 2 data suggest this therapy may help modify the disease, with topline results from late-stage studies expected in 2027.
- Intensifying Market Competition: In the same week that Immunovant reported its results, Viridian Therapeutics (VRDN) also announced its Phase 3 results for treating thyroid eye disease, which met its primary goal but showed limited improvements in inflammation, highlighting the competitive intensity in this therapeutic area.
See More
Immunovant's Phase 3 Trials Fail to Meet Primary Endpoints
- Trial Results: Immunovant's Phase 3 trials of Batoclimab for Thyroid Eye Disease failed to meet primary endpoints, resulting in an 8.12% pre-market drop to $23.06, indicating investor concerns about the company's future prospects.
- Treatment Analysis: The trials evaluated a regimen of 680mg of Batoclimab administered subcutaneously once weekly for 12 weeks, followed by 340mg weekly, but failed to achieve a 2mm or greater improvement in proptosis responder rate at Week 24, reflecting insufficient efficacy in this indication.
- Patient Response Insights: Despite not meeting primary endpoints, the studies indicated that patients showed greater proptosis improvement during the initial high-dose phase, suggesting that deeper IgG suppression may positively influence treatment outcomes, which could impact future drug development strategies.
- Future Development Plans: Immunovant intends to review future development plans for Batoclimab with partner HanAll Biopharma and remains focused on advancing IMVT-1402 across multiple autoimmune diseases, with topline data for Graves' disease expected in 2027, demonstrating the company's long-term commitment to this area.
See More
Immunovant Shares Drop 10% After Batoclimab Trial Failure
- Trial Failure Announcement: Immunovant reported that its late-stage program for batoclimab failed to meet the primary endpoint in two Phase 3 trials for thyroid eye disease, resulting in a ~10% drop in premarket shares.
- Stable Safety Data: Despite the trial failures, both studies indicated safety data consistent with previous findings, with no new safety signals, providing a foundation for future research efforts.
- Future Development Plans: The company stated it will share updates on batoclimab's development program after reviewing plans with its South Korean partner, HanAll Biopharma, indicating ongoing commitment to the project.
- Advancement of New Therapy: Immunovant intends to expedite the clinical advancement of IMVT-1402, with topline data from potentially registrational studies for Graves' disease expected next year, showcasing a new strategic direction for the company.
See More
Logos Increases Immunovant Stake to $35 Million
- Significant Stake Increase: Logos Global Management LP purchased an additional 1.1 million shares of Immunovant in Q4 2025, with an estimated transaction value of $24.5 million, reflecting strong confidence in the company's potential.
- Value Growth: By the end of the quarter, Logos' total stake in Immunovant rose to approximately $35 million, indicating a substantial increase driven by both new shares and price appreciation, highlighting its importance in the fund's portfolio.
- Portfolio Allocation Shift: The stake in Immunovant increased from 0.4% to about 2%, which, while not placing it in the top five holdings, signifies a meaningful commitment within a concentrated portfolio, showcasing Logos' focus on the biotech sector.
- Clinical Progress Monitoring: Immunovant is advancing batoclimab across multiple autoimmune indications, with key Phase 3 study results expected in the first half of 2026, which will significantly impact its regulatory trajectory.
See More
Logos Global Management Increases Immunovant Stake to 1.375 Million Shares
- Significant Stake Increase: Logos Global Management LP disclosed an increase of 1,100,000 shares in Immunovant during Q4 2025, with an estimated transaction value of $24.5 million, indicating strong confidence in the company's clinical trial progress.
- Value Growth of Holdings: This acquisition brings Logos' total holdings in Immunovant to 1,375,000 shares, valued at approximately $34.95 million, representing 2.11% of its assets under management, highlighting the fund's focus on the biotech sector.
- Strong Market Performance: As of March 13, 2026, Immunovant shares were priced at $24.72, reflecting a 29.3% increase over the past year, outperforming the S&P 500 by 10.58%, showcasing its competitive edge and investment appeal.
- Clinical Trial Developments: Immunovant's lead candidate, batoclimab, has completed Phase III trials for myasthenia gravis and is currently in Phase III trials for thyroid eye disease, with results expected in the first half of 2026, which will significantly impact its regulatory path.
See More
S&P 500 Futures Rise in Pre-Market Session; Adobe and Ulta Beauty Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Klarna Group Performance: Klarna Group PLC (KLAR) saw a 6.4% increase in pre-market trading.
Legence Corp Performance: Legence Corp. (LGN) experienced a 4.4% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate a positive sentiment ahead of the market opening.
See More
